Does enzalutamide related PSMA upregulation affect outcomes of lutetium-177 PSMA radioligand therapy?
{{output}}
Background: Enzalutamide is an antiandrogen drug used prior to lutetium-177 prostate specific membrane antigen (Lu-PSMA) radioligand therapy and has shown promising results for upregulating the PSMA expression on prostate cancer ... ...
